Loading...
•
Sep 30, 2024
ANI Pharmaceuticals Q3 2024 Earnings Report
ANI Pharmaceuticals reported record results, driven by strong performance in Rare Disease and Generics businesses, and completed the acquisition of Alimera Sciences.
Key Takeaways
ANI Pharmaceuticals reported record third-quarter net revenues of $148.3 million, a 12.5% year-over-year increase, and record Purified Cortrophin Gel net revenues of $52.6 million, a 76.8% year-over-year increase. The company reported a net loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 million. Diluted GAAP loss per share was $(1.27), and adjusted non-GAAP diluted earnings per share was $1.34. ANI completed the acquisition of Alimera Sciences and increased its 2024 guidance.
Achieved record quarterly net revenues of $148.3 million, representing a 12.5% year-over-year increase.
Reported record Purified Cortrophin Gel net revenues of $52.6 million, a 76.8% year-over-year increase.
Completed the acquisition of Alimera Sciences, adding ILUVIEN and YUTIQ to its Rare Disease portfolio.
Increased 2024 guidance for net revenues to $594 million to $602 million and adjusted non-GAAP EPS to $4.90 to $5.05.
Revenue by Segment
Forward Guidance
ANI Pharmaceuticals updated its full year 2024 guidance for the combined organization, which includes the anticipated results of Alimera from September 16, 2024.
Positive Outlook
- Net Revenue (Total Company) $594 million - $602 million
- Cortrophin Gel Net Revenue $196 million - $200 million
- ILUVIEN and YUTIQ Net Revenue $30 million - $32 million
- Adjusted Non-GAAP EBITDA $149 million - $153 million
- Adjusted Non-GAAP Diluted EPS $4.90 - $5.05
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...